Analysts expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to announce $9.42 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Sangamo Therapeutics’ earnings. The highest sales estimate is $11.20 million and the lowest is $5.85 million. Sangamo Therapeutics posted sales of $2.82 million during the same quarter last year, which suggests a positive year over year growth rate of 234%. The company is scheduled to issue its next earnings results on Wednesday, October 25th.
According to Zacks, analysts expect that Sangamo Therapeutics will report full-year sales of $9.42 million for the current year, with estimates ranging from $30.30 million to $36.40 million. For the next year, analysts expect that the business will post sales of $58.77 million per share, with estimates ranging from $16.30 million to $120.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $8.30 million for the quarter, compared to the consensus estimate of $5.82 million. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The company’s quarterly revenue was up 124.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.38) earnings per share.
A number of analysts recently weighed in on SGMO shares. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Friday, August 18th. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, September 14th. Piper Jaffray Companies set a $8.00 price objective on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Thursday, August 10th. Wells Fargo & Company reissued an “outperform” rating and issued a $30.00 price objective (up from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday, September 5th. Finally, BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. Sangamo Therapeutics currently has a consensus rating of “Hold” and an average target price of $14.40.
Sangamo Therapeutics (NASDAQ SGMO) traded down 5.66% on Friday, hitting $15.00. The stock had a trading volume of 669,914 shares. Sangamo Therapeutics has a 52-week low of $2.65 and a 52-week high of $17.06. The company’s 50 day moving average price is $14.14 and its 200 day moving average price is $9.07. The firm’s market cap is $1.25 billion.
In other news, VP Curt A. Herberts III sold 11,474 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $10.44, for a total transaction of $119,788.56. Following the transaction, the vice president now directly owns 23,991 shares of the company’s stock, valued at $250,466.04. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Curt A. Herberts III sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $15.25, for a total transaction of $228,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,474 shares of company stock worth $1,019,009. Corporate insiders own 5.50% of the company’s stock.
Several large investors have recently modified their holdings of SGMO. Blair William & Co. IL increased its position in shares of Sangamo Therapeutics by 4.3% during the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 500 shares during the period. Aperio Group LLC purchased a new position in shares of Sangamo Therapeutics during the second quarter worth approximately $108,000. Principal Financial Group Inc. increased its position in shares of Sangamo Therapeutics by 6.8% during the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 832 shares during the period. Virtu KCG Holdings LLC purchased a new position in shares of Sangamo Therapeutics during the second quarter worth approximately $124,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Sangamo Therapeutics during the second quarter worth approximately $126,000. 63.43% of the stock is currently owned by institutional investors and hedge funds.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.